TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Revolution Medicines Stock

Revolution Medicines Stock

revolutionmedicines.comHealthcareFounded: 2014Funding to Date: $226MM

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients.

Learn more about Revolution Medicines IPO
Register for Details

For more details on financing and valuation for Revolution Medicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Revolution Medicines.

Register Today

Team

Management Team

Mark Goldsmith Ph.D
President, Chief Executive Officer and Board Member
Martin Burke MD
Scientific Advisory Board Chairman & Co-Founder
Kevan Shokat Ph.D
Co-Founder & Chief Advisory Board Member
Steve Kelsey MD
President, Research & Development
Margaret Horn JD
Chief Operating Officer
Michael Fischbach Ph.D
Co-Founder & Scientific Advisory Board Member

Board Members

Alexis Borisy
Third Rock Ventures
Kevan Shokat Ph.D
Michael Fischbach Ph.D
Barbara Weber MD
Third Rock Ventures
Martin Burke MD
Vincent Miller MD
Elizabeth Anderson
Laurence Lasky Ph.D
The Column Group
Thilo Schroeder Ph.D
Nextech Invest

Other companies like Revolution Medicines in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Precision Neuroscience
Sector
Healthcare
 
 

News

Globe Newswire 02/13/2020
Revolution Medicines Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public...
Xconomy 02/12/2020
Xconomy: Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
The RAS family of proteins is one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines
FinSMEs 07/09/2019
Revolution Medicines Closes $100M Financing | FinSMEs
Revolution Medicines, Inc., a Redwood City, Calif.-based clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, closed a $100m Series C equity financing

Trending Companies

Frequently Asked Questions